What is Retatrutide
RETA also known as Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. This new-generation peptide is under investigation for extreme fat loss, metabolic acceleration, and advanced appetite suppression.
Due to its comprehensive action on multiple pathways, RETA shows superior outcomes in reducing body fat, managing blood sugar, and improving energy expenditure. For athletes, it may represent the next frontier in weight management and performance preparation.
Benefits of RETA
- Extreme fat reduction and metabolic acceleration
- Enhances energy expenditure and calorie burn
- Dramatically suppresses appetite and cravings
- Improves insulin sensitivity and glucose metabolism
- Potential to improve liver and cardiovascular markers
Research Applications
Triple Agonist Research
Retatrutide is primarily used to study:
- GLP-1, GIP, and glucagon receptor activation
- Metabolic acceleration and energy expenditure
- Appetite suppression and satiety mechanisms
- Insulin sensitivity and glucose metabolism
Previous Research Dosages Used
Clinical studies assess weekly doses starting at 2mg and increasing to 8mg or more, over a 12–24 week period.
Expected Results
Research shows significant reductions in body fat, waist circumference, and fasting glucose levels.
Certificate of Analysis
